- Home
- AMSF vs CGEM Comparison
AMSF vs CGEM Comparison
Compare AMSF & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- CGEM
- Stock Information
- Founded
- AMSF 1985
- CGEM 2016
- Country
- AMSF United States
- CGEM United States
- Employees
- AMSF N/A
- CGEM N/A
- Industry
- AMSF Accident &Health Insurance
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- CGEM Health Care
- Exchange
- AMSF Nasdaq
- CGEM Nasdaq
- Market Cap
- AMSF 857.2M
- CGEM 482.7M
- IPO Year
- AMSF 2005
- CGEM 2021
- Fundamental
- Price
- AMSF $44.07
- CGEM $5.93
- Analyst Decision
- AMSF Buy
- CGEM Strong Buy
- Analyst Count
- AMSF 2
- CGEM 8
- Target Price
- AMSF $57.50
- CGEM $27.25
- AVG Volume (30 Days)
- AMSF 84.4K
- CGEM 544.0K
- Earning Date
- AMSF 10-22-2025
- CGEM 11-06-2025
- Dividend Yield
- AMSF 10.39%
- CGEM N/A
- EPS Growth
- AMSF N/A
- CGEM N/A
- EPS
- AMSF 2.63
- CGEM N/A
- Revenue
- AMSF $306,470,000.00
- CGEM N/A
- Revenue This Year
- AMSF $2.98
- CGEM N/A
- Revenue Next Year
- AMSF $5.32
- CGEM N/A
- P/E Ratio
- AMSF $16.69
- CGEM N/A
- Revenue Growth
- AMSF N/A
- CGEM N/A
- 52 Week Low
- AMSF $42.48
- CGEM $5.90
- 52 Week High
- AMSF $60.24
- CGEM $18.62
- Technical
- Relative Strength Index (RSI)
- AMSF 42.51
- CGEM 29.91
- Support Level
- AMSF $42.63
- CGEM $6.44
- Resistance Level
- AMSF $46.53
- CGEM $6.76
- Average True Range (ATR)
- AMSF 1.00
- CGEM 0.42
- MACD
- AMSF -0.32
- CGEM -0.12
- Stochastic Oscillator
- AMSF 27.53
- CGEM 1.58
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.